Key Takeaways DHR is set to report Q3 2025 results on Oct. 21, with revenues estimated at $6.00 billion.Life Sciences may face softness, while Biotechnology gains from strong bioprocessing demand.Diagnostics likely grew modestly, aided by the Beckman Coulter unit and steady clinical demand.Danaher Corporation (DHR) is scheduled to release third-quarter 2025 results on Oct. 21, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an increase of 3.4% from th ...

Bringing together complementary technologies to serve high-volume testing in attractive and regulated end-markets: The combined company will have best-in-class liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, doubling Waters' total addressable market to approximately $40 billion. Increasing annual recurring revenue in high-quality applications: Over 70% of the combined company's revenue is expected to be recurring annually and over half of instrument revenue is expected to ...